SCHEMBL3868630

SCHEMBL3868630

O=S(=O)(NCCCCOS(=O)(=O)c1ccc(F)cc1)c1ccc(F)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.71
PKM P14618 3/20 0.71
MEN1 O00255 3/20 0.71
KMT2A Q03164 3/20 0.71
LMNA P02545 2/20 0.56
GAA P10253 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
TSHR P16473 1/20 0.48
MAPT P10636 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
KDM4E B2RXH2 1/20 0.47
HTR1A P08908 2/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
ADRA1D P25100 1/20 0.47
ADRA1A P35348 1/20 0.47
ADRA1B P35368 1/20 0.47
DRD3 P35462 1/20 0.47
HTR2A P28223 1/20 0.46
HTR2C P28335 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878739 0.85 ALDH1A1 (0.62) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL15000837 0.78 MEN1 (0.46) ALDH1A1PKMMEN1KMT2A
SCHEMBL5020896 0.78 ALDH1A1 (0.80) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL1472371 0.78 RECQL (0.50) ALDH1A1PKMMEN1KMT2ATSHR
SCHEMBL27273907 0.76 CA1 (0.42) ALDH1A1PKMMEN1KMT2ATSHR
SCHEMBL3277847 0.76 ALDH1A1 (0.77) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL27670053 0.76 CA2 (0.46) ALDH1A1PKMMEN1KMT2ATSHR
SCHEMBL15145890 0.76 ALDH1A1 (0.77) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL2009359 0.74 ALDH1A1 (0.73) ALDH1A1PKMMEN1KMT2ALMNA
SCHEMBL11348679 0.74 PKM (0.36) ALDH1A1PKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491727-B2 Good selectivity, high affinity, metabolically stable 5-HT receptor modulators with good bioavailability, CNS penetration, and good pharmacokinetic; antiserotonine agents; central nervous system disorders; anxiolytic agents; attention deficit disorders; strokes; headaches EPIX DELAWARE, INC. (US) 2009-02-17 US disclosed
US-7488731-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2009-02-10 US disclosed
US-20080027066-A1 Arylpiperazinyl Compounds EPIX DELAWARE, INC. 2008-01-31 US disclosed
EP-1592425-A4 NEW ARYLPIPERAZINYL COMPOUNDS EPIX DELAWARE INC (US) 2007-01-24 EP disclosed
US-20070004742-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2007-01-04 US disclosed
US-7153858-B2 Arylpiperazinyl compounds EPIX DELAWARE, INC. (US) 2006-12-26 US disclosed
EP-1592425-A2 NEW ARYLPIPERAZINYL COMPOUNDS Predix Pharmaceuticals Holdings, Inc. (US) 2005-11-09 EP disclosed
WO-2004069794-A9 NEW ARYLPIPERAZINYL COMPOUNDS PREDIX PHARMACEUTICALS HOLDING (US) 2004-12-09 WO disclosed
US-20040220192-A1 Arylpiperazinyl compounds EPIX DELAWARE, INC. 2004-11-04 US disclosed
WO-2004069794-A2 NEW ARYLPIPERAZINYL COMPOUNDS PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027066-A1 Arylpiperazinyl Compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885PKM 2188/4885MEN1 2363/4885
US-20070004742-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885PKM 2188/4885MEN1 2363/4885
US-20040220192-A1 Arylpiperazinyl compounds HTR5A, HTR1A, HTR2A ALDH1A1 346/4885PKM 2188/4885MEN1 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.